Format

Send to

Choose Destination
Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1167-76. doi: 10.1517/17425255.2015.1056732.

Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.

Author information

1
University of Torino, Amedeo di Savoia Hospital, Unit of Infectious Diseases, Department of Medical Sciences , C.so Svizzera 164 - 10149, Torino , Italy + 39 011 439 3884 ; + 39 011 439 3942 ; andrea.calcagno@unito.it.

Abstract

INTRODUCTION:

Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.

AREAS COVERED:

This review covers material searched and obtained through Medline and PubMed up to April 2015.

EXPERT OPINION:

Raltegravir for its tolerability, efficacy, few drug-to-drug interactions and for the amount of available data in difficult subgroups of patients is a key drug in the antiretroviral armamentarium. For its weak genetic barrier to resistance and erratic pharmacokinetic profile, it should be administered twice daily and with fully active companion antiretrovirals.

KEYWORDS:

drug-to-drug interactions; pharmacodynamic; pharmacokinetic; raltegravir; resistance

PMID:
26073580
DOI:
10.1517/17425255.2015.1056732
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center